Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...

Monness Crespi & Hardt upgraded Oracle from a sell to a neutral rating, reflecting shifting analyst sentiment. Other firms ...

Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Teladoc Health in a research report issued on Thursday, February 27th. Cantor Fitzgerald ...

Rosenblatt Securities restated their buy rating on shares of TeraWulf (NASDAQ:WULF – Free Report) in a research note released on Monday,Benzinga reports. The firm currently has a $10.00 price ...

Billionaire Giancarlo Devasini of Tether wants to maintain the stablecoin’s freedoms; his rival, Jeremy Allaire of Circle, is ...

We recently compiled a list of the 10 Best Stocks Under $50 to Buy Right Now. In this article, we are going to take a look at ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

Blackwell is still in its early days, but at $11 billion, it made up nearly a third of Nvidia's data-center revenue, Cantor Fitzgerald analyst C.J. Muse noted. (Nvidia's data-center business ...

Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...